Literature DB >> 28196621

Psoriatic arthritis disease activity during pregnancy and the first-year postpartum.

Ari Polachek1, Suzanne Li1, Inbal Shlomi Polachek2, Vinod Chandran3, Dafna Gladman4.   

Abstract

OBJECTIVES: To evaluate disease activity in the joints and skin during pregnancy and the first-year postpartum in patients with psoriatic arthritis (PsA).
METHODS: Women with PsA who were pregnant between 1990 and 2015 with at least 1 clinic visit during pregnancy were identified from the Toronto PsA database. The course of joint and skin disease activity was defined by the following 5 states: improvement, worsening, stable low, stable high, or a mixed. As controls, 67 nonpregnant PsA women were identified and evaluated over a similar timeframe.
RESULTS: Altogether, 29 PsA women with 42 pregnancies were identified. Of the 42 pregnancies, 40 (95%) resulted in normal live birth. Arthritis improved or was stable low activity in 24 (58.5%) of pregnancies. During the postpartum period, 21 (52.5%) had either improvement or stable low PsA activity, whereas 16 (40%) had either worsening or stable high disease activity. The skin activity during pregnancy either improved or stayed in a stable low state in 30 (88.2%), and in the postpartum period there was worsening in 15 (42.9%). A logistic regression analysis revealed a favourable skin disease course during the pregnancy period in the pregnant group compared to the control group (OR = 6.8, p = 0.004), but not in joint disease.
CONCLUSIONS: The outcome of pregnancy among patients with PsA is excellent. Arthritis activity trends toward a favourable course while the skin disease shows a favorable course during pregnancy. When compared to controls, pregnancy period has significant beneficial influence only on the skin but not on the joints in PsA.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Birth; Gestation; Joints; Psoriatic arthritis; Skin; Treatment

Mesh:

Year:  2017        PMID: 28196621     DOI: 10.1016/j.semarthrit.2017.01.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

1.  Reproductive health outcomes in women with psoriatic arthritis.

Authors:  Kieran Murray; Louise Moore; Fionnuala McAuliffe; Douglas J Veale
Journal:  Ann Rheum Dis       Date:  2019-02-15       Impact factor: 19.103

2.  Pregnancy outcomes, fertility, and family planning in women with psoriatic arthritis.

Authors:  Amanda M Eudy; Gary McDaniel; Megan Eb Clowse
Journal:  Obstet Med       Date:  2019-01-31

3.  Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.

Authors:  Xavier Mariette; Frauke Förger; Bincy Abraham; Ann D Flynn; Anna Moltó; René-Marc Flipo; Astrid van Tubergen; Laura Shaughnessy; Jeff Simpson; Marie Teil; Eric Helmer; Maggie Wang; Eliza F Chakravarty
Journal:  Ann Rheum Dis       Date:  2017-10-13       Impact factor: 19.103

4.  Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.

Authors:  Megan E B Clowse; Angela E Scheuerle; Christina Chambers; Anita Afzali; Alexa B Kimball; John J Cush; Maureen Cooney; Laura Shaughnessy; Mark Vanderkelen; Frauke Förger
Journal:  Arthritis Rheumatol       Date:  2018-07-22       Impact factor: 10.995

5.  Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study.

Authors:  Jennifer Strouse; Brittney M Donovan; Munazza Fatima; Ruth Fernandez-Ruiz; Rebecca J Baer; Nichole Nidey; Chelsey Forbess; Gretchen Bandoli; Randi Paynter; Nisha Parikh; Laura Jeliffe-Pawlowski; Kelli K Ryckman; Namrata Singh
Journal:  RMD Open       Date:  2019-04-14

6.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.